Medical Condition News

RSS

Digital chest tomosynthesis holds promise as first-line screening tool for lung cancer

Most lung cancers are detected when patients become symptomatic and have late-stage disease. However, recently, computed tomography creening for lung cancer has been reported to reduce lung cancer mortality.

29 May 2013

Research discovery may lead to development of new therapies for neurological disorders

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

29 May 2013

Unique omega-3 supplement improves lung function, reduces airway inflammation in asthmatics

An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

29 May 2013

Offspring of long-lived parents less prone to cancer, study reveals

The offspring of parents who live to a ripe old age are more likely to live longer themselves, and less prone to cancer and other common diseases associated with ageing, a study has revealed.

29 May 2013

Bay Pines VA Healthcare System to study effectiveness of 7-Keto compound in PTSD

The Bay Pines VA Healthcare System announced that it will begin a research study related to post-traumatic stress disorder. The study will focus on whether the use of a naturally occurring compound known as 7-Keto assists in the treatment of PTSD.

29 May 2013

Harmless genetic variations may team up to increase risk of schizophrenia, find researchers

Using a novel method of analyzing genetic variations in families, researchers at Johns Hopkins have found that individually harmless genetic variations affecting related biochemical processes may team up to increase the risk of schizophrenia.

29 May 2013

Valeant Pharmaceuticals receives Complete Response Letter from FDA for efinaconazole NDA

Valeant Pharmaceuticals International, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.

28 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes plc today presented positive results from a phase 1 study of ALKS 3831, a novel drug candidate for the treatment of schizophrenia, in an oral session at the 53rd Annual New Clinical Drug Evaluation Unit Meeting in Hollywood, Fla.

28 May 2013

New study shows childhood bullying increases risk of self-harming in later adolescence

A new study has proven that being bullied during childhood directly increases the likelihood of self- harm in late adolescence.

28 May 2013

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to asfotase alfa for the treatment of patients with hypophosphatasia (HPP) whose first signs or symptoms occurred prior to 18 years of age, including perinatal-, infantile-, and juvenile-onset forms of the disease.

28 May 2013

Parachute's Safe Kids Week 2013: Be alert. Be safe. Be aware of concussions

Twelve-year-old Nathan Fraser suffered a severe concussion during hockey practice in February 2012 when he tripped over a teammate diving for a puck and crashed head first into the ice and boards. Nathan's memory was wiped out, he lost five months of school and was so sensitive to sound and light he had to wear sunglasses and special earmuffs in his own home. After a long, slow recovery, Nathan and his family are now advocates for concussion prevention and awareness, a goal of Parachute's Safe Kids Week, May 27 to June 2.

28 May 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

Resolvins may help protect against cognitive decline after surgery

Resolvins are molecules naturally produced by the body from omega-3 fatty acids - a process that can be jumpstarted by common aspirin. In a new study, published in The FASEB Journal, researchers at Karolinska Institutet describe how resolvins could protect against the cognitive impairment that often affects recovery of surgical and critically ill patients.

28 May 2013

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Frutarom Health, Switzerland, reports increased demand for Go-Less, its natural ingredient targeting urinary incontinence in adults.

28 May 2013

New Smartphone app helps maintain accurate records to manage diabetes

Vital improvements can be made to patients diabetes control, by ensuring a recent blood glucose history is available to their Specialist Nurse. Traditionally patients have recorded their results in a paper logbook but now the new app from GlucoMen is a fantastic alternative using Smartphone technology to ensure a complete and accurate record.

28 May 2013

Medical Condition News

Digital chest tomosynthesis holds promise as first-line screening tool for lung cancer

Research discovery may lead to development of new therapies for neurological disorders

Unique omega-3 supplement improves lung function, reduces airway inflammation in asthmatics

Offspring of long-lived parents less prone to cancer, study reveals

Bay Pines VA Healthcare System to study effectiveness of 7-Keto compound in PTSD

Harmless genetic variations may team up to increase risk of schizophrenia, find researchers

Valeant Pharmaceuticals receives Complete Response Letter from FDA for efinaconazole NDA

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

New study shows childhood bullying increases risk of self-harming in later adolescence

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Parachute's Safe Kids Week 2013: Be alert. Be safe. Be aware of concussions

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Resolvins may help protect against cognitive decline after surgery

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

New Smartphone app helps maintain accurate records to manage diabetes

High comorbidity of DSM mood and anxiety disorders found among substance use disorder patients

Improved targeting of  depression treatment needed  in community settings

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Study reveals that an epilepsy drug shows promise in preventing noise-induced tinnitus

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News